Literature DB >> 7962970

Basal cell carcinoma: seven years' experience at the Institute of Dermatology in Bangkok.

Y Nakjang1, P Kullavanijaya.   

Abstract

Sixty-seven patients with basal cell carcinoma (BCC) were observed at the Institute of Dermatology, Bangkok, Thailand between 1982 and 1989. The male:female ratio was 1:2. The average age of the patients at first examination was 60.6 years. Lesions in sun-exposed areas were three times more frequent than lesions in covered areas. The principal location was the face, including the cheek, nose, periorbital area, ears, and forehead. The remainder were on the scalp, breast, abdomen, back, thigh, and knee. Ulceration was the most frequent symptom, followed by a mass. Histopathologically, pigmented BCC was the most frequent, followed by solid BCC, superficial BCC, adenoid BCC, morphoeic BCC, cystic BCC, basosquamous BCC, mixed carcinoma, keratotic BCC, and fibroepitheliomatous BCC. In patients younger than 50 years of age, solid or pigmented tumors were frequent. The morphoeic type was present only on the face and scalp. In females, solid BCC or adenoid BCC predominated. Only 4 of our 67 patients had histories of ingestion of herbal medicine with arsenic as one of the ingredients. Sixty-one patients were treated surgically. There was only one case of tumor recurrence after surgery. The remaining patients were treated by electric cautery, liquid nitrogen, or irradiation. No patients developed distant metastasis.

Entities:  

Mesh:

Year:  1994        PMID: 7962970     DOI: 10.1111/j.1346-8138.1994.tb01812.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  Evaluating the trend of cutaneous malignant tumors in Ilam from 2002 to 2011.

Authors:  Mohammad R Hafezi Ahmadi; Zeinab Bakhtari; Behrang Kazeminezhad; Samiramis Ghavam
Journal:  J Family Med Prim Care       Date:  2019-02

2.  Histopathological evaluation of non-melanoma skin cancer.

Authors:  Ali Koyuncuer
Journal:  World J Surg Oncol       Date:  2014-05-21       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.